Elixir Medical‘s novolimus-eluting stent, DeSyne, outperformed Medtronic‘s (NYSE:MDT) zotarolimus-eluting stent, Endeavor, according to long-term data from Elixir’s Excella II trial. The study enrolled 210 patients with 2 or more de novo lesions in 2 different epicardial vessels. Researchers randomly assigned patients in a 2:1 ratio to the novolimus-eluting stent or the zotarolimus-eluting stent. The device emits a low […]
Medtronic
Researchers develop 3D-printed, bioabsorbable scaffold for ACL reconstruction
Researchers at the Mayo Clinic‘s tissue engineering and biomaterials laboratory have developed a 3D-printed, porous scaffold for the delayed delivery of recombinant-human bone morphogenetic protein 2, rhBMP-2, to facilitate bone regeneration in patients undergoing ACL reconstruction. The team’s work developing the scaffold and comparing different delivery methods for rhBMP-2 was published this week in Tissue Engineering. […]
How virtual and mixed reality are changing drug delivery and device design
Kai Worrell believes that virtual and mixed reality may change the way companies design medical devices, and he’s putting that idea into practice. “We think it’s going to transform the way we do feasibility testing and cognitive walk-through simulations,” he said. “We think it’s going to help us understand the cognition of our users, clinical […]
UPDATE: Medtronic wins Health Canada license for drug-coated balloon, touts Japanese data
Medtronic (NYSE:MDT) touted 1 year data from the In.Pact SFA Japan trial of its drug-coated balloon compared to plain balloon angioplasty. The company also said today it won regulatory approval in Canada for its In.Pact Admiral DCB in patients with peripheral artery disease in the upper leg. The Japan trial enrolled 100 patients, 68 of […]
NIH launches pivotal trials for artificial pancreas
The National Institutes of Health said this week that it is funding 4 projects dedicated to testing fully automated artificial pancreas devices in patients with Type I diabetes. The race to develop an artificial pancreas met a milestone last year, after the FDA approved Medtronic’s (NYSE:MDT) hybrid model of an artificial pancreas – the 1st of its kind […]
FDA OKs Medtronic trial for In.Pact Admiral DCB in renal disease
Medtronic (NYSE:MDT) said today that the FDA approved its investigational device exemption application for a study to evaluate its In.Pact Admiral drug-coated balloon in patients with end-stage renal disease. The Fridley, Minn.-based company said that its study will compare its DCB to plain balloon angioplasty as a treatment for failing arteriovenous fistulas. The primary efficacy endpoint […]
Medtronic touts In.Pact Admiral drug-coated balloon data
Medtronic (NYSE:MDT) touted data for its In.Pact Admiral drug-coated balloon in patients with peripheral arterial disease. The company presented outcomes from its In.Pact Global study patient cohorts in Asia and Belgium, concluding that its DCB demonstrated consistent outcomes across patient populations. More than 96% of the 114-patient study group in Asia achieved positive outcomes, which […]
Researchers’ bionic pancreas outperforms standard insulin pump therapy
Researchers from Boston University have developed a bionic pancreas system that outperformed conventional insulin pump therapy for patients with type 1 diabetes, according to a trial conducted at Massachusetts General Hospital. The team’s work was published in The Lancet. This device is the latest development in the race to make an entirely closed loop insulin pump system, […]
Medtronic secures Health Canada license for MiniMed 630G system
Medtronic (NYSE:MDT) subsidiary Medtronic Canada said today that it landed a license with Health Canada for its MiniMed 630G insulin pump system for patients with diabetes mellitus. The Fridley, Minn.-based company said it interviewed more than 1,000 diabetes patients to better understand the features they look for in an insulin pump. The final product has a […]
Report: Drug device market to reach $1.8B by 2024
The global drug device combination market is expected to reach $17.7 billion by 2024, according to a new report from Grand View Research. The report points to minimally invasive alternatives like transdermal patches as high-impact growth drivers in the industry. As researchers develop these products, regulatory agencies have taken notice and the report notes that […]
